Stock Events

Stock Events

Biomarin Pharmaceutical 

$55.81
217
+$0.28+0.5%Friday 04:08

Statistics

Day High
55.81
Day Low
55.81
52W High
59.82
52W Low
49.02
Volume
20
Avg. Volume
-
Mkt Cap
10.8B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 2Expected
Q3 2025
Q1 2026
Q2 2026
Q3 2026
-0.28
0.21
0.71
1.2
Expected EPS
-0.049333
Actual EPS
0.23

Financials

10.83%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
3.22BRevenue
348.9MNet Income

Analyst Ratings

$89.07Average Price Target
The highest estimate is ⁦119.00⁩.
From 15 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BMRN.BOATS. It's not an investment recommendation.
Microsoft
51
MSFT
Amazon
51
AMZN
Apple
48
AAPL
NVIDIA
48
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals competes in the cystic fibrosis market, where both companies are looking for treatments that address the underlying cause of genetic diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is involved in genetic disorder treatments among other areas, competing with Biomarin in the broader biotech space.
AMGEN
AMGN
Mkt Cap251.94B
Amgen has a diverse biotech portfolio that includes treatments for genetic disorders, making it a competitor in the biopharmaceutical field.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, with its focus on antiviral drugs and other treatments, competes for market share in the biopharmaceutical industry.
Novo Nordisk
NVO
Mkt Cap176.43B
Novo Nordisk specializes in diabetes and obesity treatments but is expanding into biopharmaceuticals for genetic diseases, competing with Biomarin.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a broad portfolio that includes a focus on rare diseases, making it a competitor in the same space as Biomarin.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurological disorders and rare diseases, areas where Biomarin also seeks to make an impact, making them direct competitors.

About

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Show More
CEO
ISIN
US09061G1013

Listings

MI
IT
1BMRN.MI
MU
DE
BM8.MU
XNAS
US
BMRN
STU
DE
BM8.STU

0 Comments

Share your thoughts

FAQs

What is Biomarin Pharmaceutical stock price today?▼
The current price of BMRN.BOATS is $55.81 USD — it has increased by +0.5% in the past 24 hours. Watch Biomarin Pharmaceutical stock price performance more closely on the chart.
What is Biomarin Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Biomarin Pharmaceutical stocks are traded under the ticker BMRN.BOATS.
What is Biomarin Pharmaceutical market cap?▼
Today Biomarin Pharmaceutical has the market capitalization of 10.8B
When is the next Biomarin Pharmaceutical earnings date?▼
Biomarin Pharmaceutical is going to release the next earnings report on February 24, 2027.
What were Biomarin Pharmaceutical earnings last quarter?▼
BMRN.BOATS earnings for the last quarter are 0.23 USD per share, whereas the estimation was -0.05 USD resulting in a +566.22% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Biomarin Pharmaceutical revenue for the last year?▼
Biomarin Pharmaceutical revenue for the last year amounts to 3.22B USD.
What is Biomarin Pharmaceutical net income for the last year?▼
BMRN.BOATS net income for the last year is 348.9M USD.
In which sector is Biomarin Pharmaceutical located?▼
Biomarin Pharmaceutical operates in the Other sector.
When did Biomarin Pharmaceutical complete a stock split?▼
Biomarin Pharmaceutical has not had any recent stock splits.